Published in

Springer Nature [academic journals on nature.com], Cell Death and Disease, 8(5), p. e1388-e1388, 2014

DOI: 10.1038/cddis.2014.340

Springer Nature [academic journals on nature.com], Cell Death and Disease, 9(4), p. e796-e796, 2013

DOI: 10.1038/cddis.2013.315

Links

Tools

Export citation

Search in Google Scholar

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

Journal article published in 2013 by A. Muscella, C. Vetrugno, F. P. Fanizzi ORCID, C. Manca, S. A. De Pascali, S. Marsigliante
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

[Pt(O,O′-acac)(γ-acac)(DMS)] (PtAcD) is able to induce apoptosis in various human cancer cells, including the cisplatin-resistant human breast carcinoma MCF-7 cells. Here, to confirm that PtAcD has the potentiality for therapeutic intervention, we studied its effects in primary cultured epithelial breast cells obtained from cancers and also from the corresponding histologically proven non-malignant tissue adjacent to the tumor. We demonstrated that PtAcD (1) is more cytotoxic in cancer than in normal breast cells; (2) activated NAD(P)H oxidase, leading to PKC-ζ and PKC-α tanslocations; (3) activated antiapoptotic pathways based on the PKC-α, ERK1/2 and Akt kinases; (4) activated PKC-ζ and, only in cancer cell PKC-δ, responsible for the sustained phosphorylation of p38 and JNK1/2, kinases both of which are involved in the mitochondrial apoptotic process. Moreover, crosstalk between ERK/Akt and JNK/p38 pathways affected cell death and survival in PtAcD-treated breast cell. In conclusion, this study adds and extends data that highlight the pharmacological potential of PtAcD as an anti breast cancer drug.